Article Text

Download PDFPDF
Dual anti-MPO and anti-PR3 antibodies in relapsing SLE/AAV overlap
  1. Therese Boyle1,2,
  2. Suran L Fernando1,2,3
  1. 1Immunology Laboratory, New South Wales Health Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia
  2. 2Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, New South Wales, Australia
  3. 3Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Dr Therese Boyle, Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, NSW 2065, Australia; thereseboyle{at}

Statistics from

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease associated with anti-nuclear antibodies (ANA), extractable nuclear antigens (ENA), and anti-double stranded DNA antibodies. Glomerulonephritis (GN) with immune complex deposition is found in 50% of cases.1 Twenty per cent of patients with SLE have antineutrophil cytoplasmic antibodies (ANCA), which in certain patients is associated with ANCA-associated vasculitis (AAV).2 The ANCA detected in such cases is reported in the literature as antimyeloperoxidase antibodies (MPO) rather than antiproteinase 3 (PR3) antibodies.3 The prevalence of dual-positive AAV is up to 9% but these cases are not associated with SLE.4 This is the first report of a case of SLE/AAV involving AAV (necrotising pauci-immune GN) with both anti-MPO and anti-PR3 antibodies.

A 70-year-old woman presented with thrombocytopenia (platelets 17×109/L), renal failure (creatinine 260 µmol/L) and deep vein thrombosis. She has a 10-year history of SLE characterised by panniculitis, photosensitivity, polyarthritis, oral ulceration, sicca symptoms, relapsing polychondritis, pulmonary hypertension, interstitial lung disease and pulmonary thromboembolism due to secondary antiphospholipid syndrome. Her laboratory investigations revealed a high titre (>2560) homogeneous ANA, anti-double-stranded-DNA antibodies and persistently elevated anticardiolipin and anti-beta-2 glycoprotein 1 antibodies. Her symptoms were non-responsive to methotrexate and leflunomide. A renal biopsy performed 1 year prior to presentation for a creatinine 110 µmol/L demonstrated hypertensive changes with no features of …

View Full Text


  • Handling editor Stephen R A Jolles.

  • Contributors Patient care managed by SLF. Planning, conduct and reporting completed by SLF. Case report reviewed and edited by both authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.